PCSK9 and infection: A potentially useful or dangerous association?

PCSK9 at the crossroad of cholesterol metabolism and immune function during infections

(2017) Francesco Paciullo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

(2016) Peter H. Jones et al.   AMERICAN JOURNAL OF CARDIOLOGY

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

(2016) Piotr Chruściel et al.   ATHEROSCLEROSIS

PCSK9 inhibitors in sepsis: a new potential indication?

(2016) Amir Abbas Momtazi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Two proprotein convertase subtilisin/kexin type 9 (PCSK9) paralogs from the tropical sea cucumber ( Stichopus monotuberculatus ): Molecular characterization and inducible expression with immune challenge

(2016) Chunhua Ren et al.   FISH & SHELLFISH IMMUNOLOGY

Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury

(2016) Yang Zhang et al.   International Journal of Biological Sciences

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis

(2016) John H. Boyd et al.   Journal of Innate Immunity

A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients

(2016) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis

(2016) Dhruva J. Dwivedi et al.   SHOCK

Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus

(2016) Satomi Yamamoto et al.   PLoS Pathogens

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

(2016) Payal Kohli et al.   Journal of the American Heart Association

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

(2016) Aarti Ramanathan et al.   PLoS One

Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor

(2016) Elena Topchiy et al.   PLoS One

Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta

(2015) Zufeng Ding et al.   ANTIOXIDANTS & REDOX SIGNALING

Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

(2015) Amirhossein Sahebkar et al.   ATHEROSCLEROSIS

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

(2015) Maciej Banach et al.   BMC Medicine

Cross-talk between LOX-1 and PCSK9 in vascular tissues

(2015) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

PCSK9 inhibitors – past, present and future

(2015) Željko Reiner   Expert Opinion on Drug Metabolism & Toxicology

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism

(2015) Simon H. Bridge et al.   JOURNAL OF HEPATOLOGY

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipids, blood pressure and kidney update 2014

(2015) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Hepatitis C virus utilizes VLDLR as a novel entry pathway

(2015) Saneyuki Ujino et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials

(2015) Gianna Ferretti et al.   PROGRESS IN LIPID RESEARCH

Association between statin use and plasma D-dimer levels

(2015) Dimitri Mikhailidis et al.   THROMBOSIS AND HAEMOSTASIS

A cholesterol-lowering VLP vaccine that targets PCSK9

(2015) Erin Crossey et al.   VACCINE

A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

(2015) Corina Serban et al.   Scientific Reports

PCSK9 and LDLR degradation

(2014) Thomas A. Lagace   CURRENT OPINION IN LIPIDOLOGY

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

(2014) K. R. Walley et al.   Science Translational Medicine

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

(2013) Amirhossein Sahebkar et al.   CARDIOVASCULAR DRUGS AND THERAPY

New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes

(2013) Amirhossein Sahebkar et al.   CLINICAL THERAPEUTICS

Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport

(2013) Li Shen et al.   FEBS LETTERS

Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation

(2013) G. H. Syed et al.   JOURNAL OF VIROLOGY

My road to Damascus: how I converted to the prohormone theory and the proprotein convertases

(2012) Michel Chrétien   Biochemistry and Cell Biology

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice

(2012) Haruna Miyazawa et al.   Lipids in Health and Disease

Hepatitis C Virus Infection and the Rising Incidence of Hepatocellular Carcinoma

(2012) Denise M. Harnois   MAYO CLINIC PROCEEDINGS

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C virus host cell entry

(2012) Alexander Ploss et al.   Current Opinion in Virology

Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration

(2011) Haruna Miyazawa et al.   CLINICA CHIMICA ACTA

Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial

(2011) Seyyed M. R. Parizadeh et al.   LIPIDS

PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression

(2009) Patrick Labonté et al.   HEPATOLOGY

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA